FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2184710012> ?p ?o ?g. }

• W2184710012 endingPage "90" @default.
• W2184710012 startingPage "73" @default.
• W2184710012 abstract "Panic disorder with agoraphobia (PDA) is considered an important public health problem. The efficacy of cognitive-behavioral therapy (CBT) for PDA has been widely demonstrated. The American National Institute of Health recommended Cognitive-Behavioral programs as the treatment of choice for this disorder. This institution also recommended that researchers develop treatments whose mode of delivery increases the availability of these programs. Virtual Reality based treatments can help to achieve this goal. VR has several advantages compared with conventional techniques. One of the essential components to treat these disorders is exposure. In VR the therapist can control the feared situations at will and with a high degree of safety for the patient, as it is easier to grade the feared situations. Another advantage is that VR is more confidential because treatment takes place in the therapist's office. It is also less time consuming as it takes place in the therapist's office. Considering the wide number of situations and activities that agoraphobic patients use to avoid, VR can save time and money significantly. Another advantage in treating PDA using VR is the possibility of doing VR interoceptive. VR could be a more natural setting for interoceptive exposure than the consultation room because we can elicit bodily sensations while the patient is immerse in VR agoraphobic situations. Finally, we think that VR exposure can be a useful intermediate step for those patients who refuse in vivo exposure because the idea of facing the real agoraphobic situations is too aversive for them. In this chapter we offer the work done by our research team at the VEPSY-UPDATED project. We describe the VR program we have developed for the treatment of PDA and we summarize the efficacy and effectiveness data of a study where we compare a cognitive-behavioral program including VR for the exposure component with a standard cognitive-behavioral program including in vivo exposure and with a waiting list control condition. Our findings support the efficacy and effectiveness of VR for the treatment of PDA." @default.
• W2184710012 created "2016-06-24" @default.
• W2184710012 creator A5020295603 @default.
• W2184710012 creator A5020729884 @default.
• W2184710012 creator A5026061571 @default.
• W2184710012 creator A5045968887 @default.
• W2184710012 creator A5058337569 @default.
• W2184710012 creator A5077764832 @default.
• W2184710012 date "2004-01-01" @default.
• W2184710012 modified "2023-09-24" @default.
• W2184710012 title "The use of VR in the treatment of panic disorders and agoraphobia." @default.
• W2184710012 cites W1510446882 @default.
• W2184710012 cites W1516567210 @default.
• W2184710012 cites W1544362783 @default.
• W2184710012 cites W1572954557 @default.
• W2184710012 cites W1972528623 @default.
• W2184710012 cites W1996316847 @default.
• W2184710012 cites W1999917332 @default.
• W2184710012 cites W2013007348 @default.
• W2184710012 cites W2017817022 @default.
• W2184710012 cites W2021832371 @default.
• W2184710012 cites W2023124281 @default.
• W2184710012 cites W2025733498 @default.
• W2184710012 cites W2031893564 @default.
• W2184710012 cites W2034477833 @default.
• W2184710012 cites W2066530745 @default.
• W2184710012 cites W2066807621 @default.
• W2184710012 cites W2067201491 @default.
• W2184710012 cites W2067495470 @default.
• W2184710012 cites W2076455297 @default.
• W2184710012 cites W2076521240 @default.
• W2184710012 cites W2081739393 @default.
• W2184710012 cites W2099630103 @default.
• W2184710012 cites W2111943567 @default.
• W2184710012 cites W2112925388 @default.
• W2184710012 cites W2125940695 @default.
• W2184710012 cites W2149746542 @default.
• W2184710012 cites W2159011576 @default.
• W2184710012 cites W2159061031 @default.
• W2184710012 cites W2160600342 @default.
• W2184710012 cites W2263739033 @default.
• W2184710012 cites W2953589629 @default.
• W2184710012 cites W2957777837 @default.
• W2184710012 cites W3090293687 @default.
• W2184710012 doi "https://doi.org/10.3233/978-1-60750-943-1-73" @default.
• W2184710012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15295147" @default.
• W2184710012 hasPublicationYear "2004" @default.
• W2184710012 type Work @default.
• W2184710012 sameAs 2184710012 @default.
• W2184710012 citedByCount "7" @default.
• W2184710012 countsByYear W21847100122016 @default.
• W2184710012 crossrefType "journal-article" @default.
• W2184710012 hasAuthorship W2184710012A5020295603 @default.
• W2184710012 hasAuthorship W2184710012A5020729884 @default.
• W2184710012 hasAuthorship W2184710012A5026061571 @default.
• W2184710012 hasAuthorship W2184710012A5045968887 @default.
• W2184710012 hasAuthorship W2184710012A5058337569 @default.
• W2184710012 hasAuthorship W2184710012A5077764832 @default.
• W2184710012 hasConcept C107457646 @default.
• W2184710012 hasConcept C118552586 @default.
• W2184710012 hasConcept C15744967 @default.
• W2184710012 hasConcept C169900460 @default.
• W2184710012 hasConcept C194969405 @default.
• W2184710012 hasConcept C2777527207 @default.
• W2184710012 hasConcept C2777529043 @default.
• W2184710012 hasConcept C2778251122 @default.
• W2184710012 hasConcept C2778458363 @default.
• W2184710012 hasConcept C2778678127 @default.
• W2184710012 hasConcept C2780712732 @default.
• W2184710012 hasConcept C38652104 @default.
• W2184710012 hasConcept C41008148 @default.
• W2184710012 hasConcept C542102704 @default.
• W2184710012 hasConcept C558461103 @default.
• W2184710012 hasConcept C71745522 @default.
• W2184710012 hasConcept C71924100 @default.
• W2184710012 hasConceptScore W2184710012C107457646 @default.
• W2184710012 hasConceptScore W2184710012C118552586 @default.
• W2184710012 hasConceptScore W2184710012C15744967 @default.
• W2184710012 hasConceptScore W2184710012C169900460 @default.
• W2184710012 hasConceptScore W2184710012C194969405 @default.
• W2184710012 hasConceptScore W2184710012C2777527207 @default.
• W2184710012 hasConceptScore W2184710012C2777529043 @default.
• W2184710012 hasConceptScore W2184710012C2778251122 @default.
• W2184710012 hasConceptScore W2184710012C2778458363 @default.
• W2184710012 hasConceptScore W2184710012C2778678127 @default.
• W2184710012 hasConceptScore W2184710012C2780712732 @default.
• W2184710012 hasConceptScore W2184710012C38652104 @default.
• W2184710012 hasConceptScore W2184710012C41008148 @default.
• W2184710012 hasConceptScore W2184710012C542102704 @default.
• W2184710012 hasConceptScore W2184710012C558461103 @default.
• W2184710012 hasConceptScore W2184710012C71745522 @default.
• W2184710012 hasConceptScore W2184710012C71924100 @default.
• W2184710012 hasLocation W21847100121 @default.
• W2184710012 hasLocation W21847100122 @default.
• W2184710012 hasOpenAccess W2184710012 @default.
• W2184710012 hasPrimaryLocation W21847100121 @default.
• W2184710012 hasRelatedWork W138957182 @default.
• W2184710012 hasRelatedWork W1973720603 @default.

• next